Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price target on Sanofi SA (EPA:SAN) in a research note issued to investors on Tuesday. The firm currently has a neutral rating on the stock.

Other equities analysts have also recently issued research reports about the company. J P Morgan Chase & Co set a €90.00 ($105.88) price objective on Sanofi SA and gave the company a neutral rating in a report on Tuesday, August 1st. S&P Global set a €90.00 ($105.88) price objective on Sanofi SA and gave the company a neutral rating in a report on Monday, July 31st. Sanford C. Bernstein set a €90.00 ($105.88) target price on Sanofi SA and gave the company a neutral rating in a research report on Monday, July 31st. Jefferies Group LLC set a €87.00 ($102.35) target price on Sanofi SA and gave the company a neutral rating in a research report on Thursday, August 24th. Finally, BNP Paribas set a €85.00 ($100.00) target price on Sanofi SA and gave the company a neutral rating in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of €88.12 ($103.67).

Sanofi SA (EPA:SAN) opened at 83.81 on Tuesday. The stock has a 50 day moving average price of €26.13 and a 200-day moving average price of €26.02. The firm has a market cap of €105.24 billion and a P/E ratio of 11.69. Sanofi SA has a one year low of €24.55 and a one year high of €84.55.

TRADEMARK VIOLATION NOTICE: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/sanofi-sa-san-pt-set-at-82-00-by-goldman-sachs-group-inc-the/1644584.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.